These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11247187)

  • 41. [Physiopathological and chemopathological mechanisms of central motor disorders in amyotrophic lateral sclerosis].
    Aĭrapetian KV; Zavalishin IA; Nikitin SS; Barkhatova VP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(7):33-6. PubMed ID: 10957798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
    Murphy AC; Lalor SJ; Lynch MA; Mills KH
    Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-cell responses to neurofilament light protein are part of the normal immune repertoire.
    Huizinga R; Hintzen RQ; Assink K; van Meurs M; Amor S
    Int Immunol; 2009 Apr; 21(4):433-41. PubMed ID: 19240089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis.
    Tischner D; Weishaupt A; van den Brandt J; Müller N; Beyersdorf N; Ip CW; Toyka KV; Hünig T; Gold R; Kerkau T; Reichardt HM
    Brain; 2006 Oct; 129(Pt 10):2635-47. PubMed ID: 16921176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.
    Noronha A; Toscas A; Jensen MA
    Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Suppressor cell activity in multiple sclerosis and other nervous system diseases. Preliminary report].
    Czernicki J; Offierska M; Maciejek Z; Tchórzewski H; Chmielewski H
    Neurol Neurochir Pol; 1981; 15(3):283-9. PubMed ID: 6458774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis.
    Buntinx M; Moreels M; Vandenabeele F; Lambrichts I; Raus J; Steels P; Stinissen P; Ameloot M
    J Neurosci Res; 2004 Jun; 76(6):834-45. PubMed ID: 15160395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.
    Feger U; Luther C; Poeschel S; Melms A; Tolosa E; Wiendl H
    Clin Exp Immunol; 2007 Mar; 147(3):412-8. PubMed ID: 17302889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathological and protective effects of tumor necrosis factor-alpha in multiple sclerosis].
    Smagina IV; Elchaninova SA; Palashchenko AS; Galaktionova LP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):14-20. PubMed ID: 31934984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oligodendroglial toxicity by serum and lymphocytes from patients with multiple sclerosis.
    Fewster ME; Ellison GW; Myers LW; Kirashige EY
    Neurology; 1975 Aug; 25(8):735-9. PubMed ID: 1080263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neurotransmitters in mechanisms of relations between nervous and immune systems in multiple sclerosis].
    Barkhatova VP; Zavalishin IA; Khaĭderov BT
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(11):51-4. PubMed ID: 9845945
    [No Abstract]   [Full Text] [Related]  

  • 52. Changes in immune function in relapsing multiple sclerosis correlate with disease activity as assessed by magnetic resonance imaging.
    Oger J; O'Gorman M; Willoughby E; Li D; Paty DW
    Ann N Y Acad Sci; 1988; 540():597-601. PubMed ID: 2974690
    [No Abstract]   [Full Text] [Related]  

  • 53. Differential aspects of cytokines in the immunopathology of multiple sclerosis.
    Lucas K; Hohlfeld R
    Neurology; 1995 Jun; 45(6 Suppl 6):S4-5. PubMed ID: 7783911
    [No Abstract]   [Full Text] [Related]  

  • 54. Immune-mediated mechanisms in multiple sclerosis.
    Fuchs D; Reibnegger G; Werner ER; Wachter H
    J Neurol; 1990 Apr; 237(2):125. PubMed ID: 2355238
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pathochemical problems of multiple sclerosis].
    BAUER H
    Medizinische; 1956 Jul; 7(29-30):1019-23. PubMed ID: 13358434
    [No Abstract]   [Full Text] [Related]  

  • 56. [Neurotransmitter changes in multiple sclerosis].
    Barkhatova VP; Zavalishin IA; Askarova LSh; Shavratskiĭ VKh; Demina EG
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(5):7-10. PubMed ID: 9245166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Biochemical mechanisms of impaired neuroimmune interaction in multiple sclerosis].
    Barkhatova BP; Zavalishin IA; Khaĭdarov BT; Demina EG; Shavratskiĭ VKh
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(11):42-6. PubMed ID: 11247187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis.
    Vanderlocht J; Hellings N; Hendriks JJ; Vandenabeele F; Moreels M; Buntinx M; Hoekstra D; Antel JP; Stinissen P
    J Neurosci Res; 2006 Apr; 83(5):763-74. PubMed ID: 16477612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pathogenesis of multiple sclerosis: status of research].
    Hartung HP
    Wien Med Wochenschr; 1996; 146(19-20):520-7. PubMed ID: 9082652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cytokines in MS lesion].
    Kato H; Suzumura A
    Nihon Rinsho; 2003 Aug; 61(8):1428-34. PubMed ID: 12962034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.